S&P 500   4,594.62
DOW   34,899.34
QQQ   391.20
S&P 500   4,594.62
DOW   34,899.34
QQQ   391.20
S&P 500   4,594.62
DOW   34,899.34
QQQ   391.20
S&P 500   4,594.62
DOW   34,899.34
QQQ   391.20

Albireo Pharma Stock Forecast, Price & News

-1.41 (-5.60%)
(As of 11/26/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
136,158 shs
Average Volume
184,934 shs
Market Capitalization
$458.45 million
P/E Ratio
Dividend Yield
30 days | 90 days | 365 days | Advanced Chart
Receive ALBO News and Ratings via Email

Sign-up to receive the latest news and ratings for Albireo Pharma and its competitors with MarketBeat's FREE daily newsletter.

Albireo Pharma logo

About Albireo Pharma

Albireo Pharma, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of novel bile acid modulators for the treatment of orphan pediatric liver diseases and gastrointestinal disorders. Its pipeline products include Odevixibat, A3384, and Elobixibat. The company was founded by Jan Peter Mattsson and Per-Göran Gillberg on December 8, 2003 and is headquartered in Boston, MA.


Albireo Pharma (NASDAQ:ALBO) Hits New 12-Month Low at $27.16
November 16, 2021 |  americanbankingnews.com
Albireo Pharma Inc
November 6, 2021 |  reuters.com
See More Headlines

Industry, Sector and Symbol

Pharmaceutical preparations
Current Symbol
Year Founded

Sales & Book Value

Annual Sales
$8.31 million
Book Value
$9.43 per share


Net Income
$-107.63 million
Net Margins
Pretax Margin




Free Float
Market Cap
$458.45 million

Company Calendar

Last Earnings
Fiscal Year End
Next Earnings (Estimated)

Social Links


Overall MarketRank

2.08 out of 5 stars

Medical Sector

508th out of 1,392 stocks

Pharmaceutical Preparations Industry

239th out of 670 stocks

Analyst Opinion: 3.5Community Rank: 4.4Dividend Strength: 0.0Insider Behavior: 2.5Valuation: 0.0 5 -4 -3 -2 -1 -

Albireo Pharma (NASDAQ:ALBO) Frequently Asked Questions

Is Albireo Pharma a buy right now?

5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Albireo Pharma in the last twelve months. There are currently 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Albireo Pharma stock.
View analyst ratings for Albireo Pharma
or view top-rated stocks.

How has Albireo Pharma's stock price been impacted by Coronavirus?

Albireo Pharma's stock was trading at $17.63 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, ALBO stock has increased by 34.9% and is now trading at $23.78.
View which stocks have been most impacted by COVID-19

When is Albireo Pharma's next earnings date?

Albireo Pharma is scheduled to release its next quarterly earnings announcement on Thursday, February 24th 2022.
View our earnings forecast for Albireo Pharma

How were Albireo Pharma's earnings last quarter?

Albireo Pharma, Inc. (NASDAQ:ALBO) announced its quarterly earnings data on Thursday, November, 4th. The biopharmaceutical company reported $2.90 EPS for the quarter, topping the consensus estimate of ($0.38) by $3.28. Albireo Pharma had a negative trailing twelve-month return on equity of 82.99% and a negative net margin of 444.28%. During the same period last year, the business posted ($1.96) EPS.
View Albireo Pharma's earnings history

What price target have analysts set for ALBO?

5 brokers have issued 12 month target prices for Albireo Pharma's shares. Their forecasts range from $72.00 to $84.00. On average, they anticipate Albireo Pharma's share price to reach $79.80 in the next year. This suggests a possible upside of 235.6% from the stock's current price.
View analysts' price targets for Albireo Pharma
or view top-rated stocks among Wall Street analysts.

Who are Albireo Pharma's key executives?

Albireo Pharma's management team includes the following people:
  • Ronald H. W. Cooper, President, Chief Executive Officer & Director
  • Simon John Harford, Chief Financial Officer & Treasurer (LinkedIn Profile)
  • Jan Peter Mattsson, Chief Scientific Officer, Managing Director-Sweden
  • Patrick Taylor Horn, Chief Medical Officer
  • Joan Connolly, Chief Technology Officer

What other stocks do shareholders of Albireo Pharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Albireo Pharma investors own include Energy Transfer (ET), Heat Biologics (HTBX), Amarin (AMRN), Exelixis (EXEL), Palatin Technologies (PTN), GW Pharmaceuticals (GWPH), Viking Therapeutics (VKTX), Agenus (AGEN), OPKO Health (OPK) and Pfizer (PFE).

What is Albireo Pharma's stock symbol?

Albireo Pharma trades on the NASDAQ under the ticker symbol "ALBO."

Who are Albireo Pharma's major shareholders?

Albireo Pharma's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (6.01%), Chicago Capital LLC (4.26%), ArrowMark Colorado Holdings LLC (3.27%), Rice Hall James & Associates LLC (2.64%), Prosight Management LP (2.31%) and Dimensional Fund Advisors LP (1.63%). Company insiders that own Albireo Pharma stock include Jan Mattsson, Jan Mattsson, Jason Duncan, Life Sciences Maste Perceptive, Martha J Carter, Pamela Stephenson, Patrick Taylor Horn, Perceptive Advisors Llc and Simon NR Harford.
View institutional ownership trends for Albireo Pharma

Which institutional investors are selling Albireo Pharma stock?

ALBO stock was sold by a variety of institutional investors in the last quarter, including Two Sigma Advisers LP, Dimensional Fund Advisors LP, ArrowMark Colorado Holdings LLC, BlackRock Inc., Marshall Wace LLP, Citigroup Inc., New York State Common Retirement Fund, and Rice Hall James & Associates LLC. Company insiders that have sold Albireo Pharma company stock in the last year include Jan Mattsson, Jason Duncan, Pamela Stephenson, Patrick Taylor Horn, and Simon NR Harford.
View insider buying and selling activity for Albireo Pharma
or view top insider-selling stocks.

Which institutional investors are buying Albireo Pharma stock?

ALBO stock was purchased by a variety of institutional investors in the last quarter, including Chicago Capital LLC, Prosight Management LP, Platinum Investment Management Ltd., Millennium Management LLC, Goldman Sachs Group Inc., Jane Street Group LLC, GSA Capital Partners LLP, and Martingale Asset Management L P. Company insiders that have bought Albireo Pharma stock in the last two years include Life Sciences Maste Perceptive, and Perceptive Advisors Llc.
View insider buying and selling activity for Albireo Pharma
or or view top insider-buying stocks.

How do I buy shares of Albireo Pharma?

Shares of ALBO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Albireo Pharma's stock price today?

One share of ALBO stock can currently be purchased for approximately $23.78.

How much money does Albireo Pharma make?

Albireo Pharma has a market capitalization of $458.45 million and generates $8.31 million in revenue each year. The biopharmaceutical company earns $-107.63 million in net income (profit) each year or ($2.59) on an earnings per share basis.

How many employees does Albireo Pharma have?

Albireo Pharma employs 90 workers across the globe.

When was Albireo Pharma founded?

Albireo Pharma was founded in 2003.

What is Albireo Pharma's official website?

The official website for Albireo Pharma is www.albireopharma.com.

Where are Albireo Pharma's headquarters?

Albireo Pharma is headquartered at 10 POST OFFICE SQUARE SUITE 502 SOUTH, BOSTON MA, 02109.

How can I contact Albireo Pharma?

Albireo Pharma's mailing address is 10 POST OFFICE SQUARE SUITE 502 SOUTH, BOSTON MA, 02109. The biopharmaceutical company can be reached via phone at (857) 254-5555, via email at [email protected], or via fax at 203-796-5001.

This page was last updated on 11/27/2021 by MarketBeat.com Staff


Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.